이전|다음

데이터 마이닝 기술을 활용한 장파롱의 2형 당뇨병 핵심 처방 분석 및 임상 효과

  • role： First author第一作者
  • Affiliation：

    Chengdu Shuangliu Hospital of Traditional Chinese Medicine（TCM），Chengdu 610200，China

  • Email：1227486514@qq.com
  • Introduction：方威，硕士，主治医师，从事中医药防治内分泌及代谢性疾病研究，E-mail：1227486514@qq.com
FANG Wei1,  
  • Affiliation：

    Chengdu Shuangliu Hospital of Traditional Chinese Medicine（TCM），Chengdu 610200，China

XU Jie1,  
  • Affiliation：

    Chengdu Shuangliu Hospital of Traditional Chinese Medicine（TCM），Chengdu 610200，China

WANG Huanping1,  
  • Affiliation：

    Hospital of Chengdu University of TCM，Chengdu 610072，China

ZHANG Xiaoran2,  
  • role： Corresponding author通信作者
  • Affiliation：

    Chengdu Shuangliu Hospital of Traditional Chinese Medicine（TCM），Chengdu 610200，China

  • Email：2780019047@qq.com
  • Introduction：朱红霞，硕士，主任医师，从事内分泌及代谢性疾病研究，E-mail：2780019047@qq.com；
ZHU Hongxia1*,  
  • role： Corresponding author通信作者
  • Affiliation：

    Hospital of Chengdu University of TCM，Chengdu 610072，China

  • Email：chenqiu1969@163.com
  • Introduction：陈秋，博士，教授，主任医师，从事中医药防治内分泌及代谢性疾病研究，E-mail：chenqiu1969@163.com
CHEN Qiu2*

추상적인

목적은 장파롱 교수의 2형 당뇨병 치료약물 규칙과 핵심 처방의 임상 효과를 탐구하는 것이었다. 방법은 장파롱 교수의 2형 당뇨병의 임상 의학 사례를 수집하여 처방 데이터베이스를 구축하고, 빈도 분석, 시각적 분석 및 인자 분석 등의 방법을 적용하여 장파롱 교수의 임상 처방 약물의 특징과 접근 방식을 밝혀서 핵심 처방을 정리했다. 병렬 대조 임상 시험을 실시하여 습한 발열형 2형 당뇨병 환자 60명을 관찰군(핵심 처방+메트포르민)과 대조군(메트포르민 단일 약물)으로 나누었으며, 두 그룹의 치료 기간은 모두 12주간으로 설정하고, 치료 전후 두 그룹의 중의학증후평가 점수, 당대사 지표[공복혈당(FPG), 식후 2시간 혈당(2 hPG), 글리코합성혈색소(HbA1c)], 비장 기능[공복 C펩타이드(FCP), 식후 2 시간 C펩타이드(2 hCP), C펩타이드 曲线　下面积(AUCcp)] 및 혈지의 변화를 관찰하고 그의 부작용을 통계적으로 분석했다. 결과로는 콩주、황련、황금、황기、디골피、상백피、계내금、숙지황、창출、황경、훼향 등 11가지 한약으로 구성된 핵심 처방을 정리하고 가미콩주금련탕이라 명명하였다. 후속 임성 시험 결과, 해당 그룹의 치료전과 비교하여 치료 후 두 그룹의 FPG, 2 hPG, HbA1c는 모두 유의하게 감소하였으며, 관찰군의 HbA1c가 대조군보다 우수하였으며, 치료 후 두 그룹은 모두 중의학증후평가 점수가 유의하게 감소하였으며, 관찰군이 대조군보다 우수하였으며, 치료 후 관찰군의 TC, LDL-C가 유의하게 감소하였으며, 대조군은 혈지에 개선 경향이 있지만 차이는 통계적으로 유의성이 없었으며, 치료 후 두 그룹의 FCP, AUCcp가 모두 유의하게 증가하였으며, 2 hCP의 두 그룹 모두 개선하는 경향이 있지만 통계적으로 유의성이 없었다. 두 그룹의 부작용 발생률 비교한 결과는 통계적으로 유의성이 없었다. 결론은 가미콩주금련탕은 장파롱 교수의 치통탈、포비콩 신、익기음、청허열、통유络、허유합치 의 학문적 사고를 반영하며 메트포르민과 협조하여 습한 발열형 2형 당뇨병 환자의 임상 증상을 개선하며, 비장기능 회복, 혈당과 혈지 수준을 통제하는 효과가 있었으며, 습한 발열형 2형 당뇨병 환자를 구분하여 유효한 치료 수단이었으며, 임상적으로 보급 적용할 가치가 있다.

키워드

데이터 마이닝, 장파롱 교수, 2형 당뇨병, 약물 규칙, 임상 연구

References

  1. 1.
    CHEW N W S，NG C H，TAN D J H，et al.The global burden of metabolic disease：Data from 2000 to 2019［J］.Cell Metab，2023，35（3）：414-428.
  2. 2.
    GBD 2021 Diabetes Collaborators.Global，regional，and national burden of diabetes from 1990 to 2021，with projections of prevalence to 2050：A systematic analysis for the Global Burden of Disease Study 2021［J］.Lancet，2023，402（10397）：203-234.
  3. 3.
    Chinese Diabetes Society of Chinese Medical Association.Guideline for the prevention and treatment of type 2 diabetes mellitus in China （2020 edition）［J］.Chin J Diabetes，2021，13（4）：315-409.
  4. 4.
    LEI D C，ZHANG L L，ZHOU S P，et al.Current status and research progress on traditional Chinese medicine in the treatment of diabetes mellitus［J］.China Med Her，2012，9（21）：8-9，12.
  5. 5.
    CAI R S，YI Y.Traditional Chinese medicine treatment for diabetes and its complications：A review［J］.Chin J Exp Tradit Med Form，2024，30（17）：275-283.
  6. 6.
    XIANG J Q，WEI W J，LIAO M H，et al. Mitigation of renal microvascular injury in diabetic kidney disease model mice by electroacupuncture［J］. World J Acupunct Moxibust，2023，33（3）：262-272.
  7. 7.
    CUI H Y，SHAO M Y，ZHAO R X，et al.Research ideas on human experience in medical cases of classic formulas based on evidence-based concept［J］.J Tradit Chin Med，2024，65（22）：2310-2315.
  8. 8.
    TAO Z，XU Z M，GUO Y，et al.Application and trend of data mining in inheritance of famous traditional Chinese medicine experts' experience［J］.World Chin Med，2023，18（13）：1918-1922，1927.
  9. 9.
    NI Q，P Q，YANG Y N，et al.Guidelines for traditional Chinese medicine in prevention and treatment of type 2 diabetes mellitus［J］.Global Tradit Chin Med，2024，17（5）：973-982.
  10. 10.
    Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China （2020 Edition）［M］.Beijing：China Medical Science and Technology Press，2020.
  11. 11.
    ZHANG T M.Chinese Materia Medica［M］.Shanghai：Shanghai Scientific and Technical Publishers，2012.
  12. 12.
    XU H Z，XU Z Y，CHEN P J.Study on professor XU Zhenye's medication rule in prescriptions for treating lung cancer of spleen and kidney deficiency syndrome based on data mining［J］.Mod Tradit Chin Med Mater Med-World Sci Technol，2023，25（4）：1217-1223.
  13. 13.
    ZHANG C Y，YU M，CHEN R C，et al.Research progress on the pharmacological effects of Codonopsis Radix［J］.Tradit Chin Drug Res Clin Pharmacol，2024，35（5）：765-770.
  14. 14.
    ZHENG Z Q.Analysis of the hypoglycemic effect of rhein based on structural characteristics of gut microbiota in type 2 diabetes mellitus［D］.Guangzhou：Southern Medical University，2020.
  15. 15.
    LIN C X.Hypoglycemic and hypolipidemic effects and mechanisms of Qingqianliu double melon herbal tea bags in type 2 diabetic rats［D］.Nanning：Guangxi Medical University，2018.
  16. 16.
    HU B.Clinical experience and academic thoughts of professor ZHANG Farong［D］.Chengdu：Chengdu University of Traditional Chinese Medicine，2015.
  17. 17.
    GOU X W，ZHAO L H，HE L S，et al.Strategy of traditional Chinese medicine to treat type 2 diabetes from perspective of "state-target" strategy［J］.Liaoning J Tradit Chin Med，2020，47（4）：1-4.
  18. 18.
    ZHENG X Y.Guidelines for Clinical Research of New Traditional Chinese Medicine Drugs （Trial）［M］.Beijing：China Medical Science and Technology Press，2002.
  19. 19.
    TONG X L，JI H Y，LI M，et al.New Discussion of Pi-dan［J］.China J Tradit Chin Med Pharm，2009，24（8）：988-991.
  20. 20.
    FANG W，LIAO T T.Experience of professor ZHANG Farong in differentiating and treating diabetes［J］.Sichuan J Tradit Chin Med，2021，39（4）：1-3.
  21. 21.
    WEI J P，LIU F，ZHOU L B，et al.Epidemiological investigation on risk factors of impaired glucose tolerance and diabetes mellitus and traditional Chinese medicine syndromes in beijing［J］.Beijing J Tradit Chin Med，2010，29（10）：731-737.
  22. 22.
    CHEN Z P，HUANG Y Q，CUI Z L，et al.Treatment of diabetic nephropathy with Jingui Shenqi pills based on the "state-target strategy"［J］.World Chin Med，2023，18（2）：277-280.
  23. 23.
    ZHANG Z D，LI G X，LI M，et al.Research on connotation construction and innovative methods of experience inheritance of distinguished veteran traditional Chinese medicine physicians［J］.China J Basic Med Tradit Chin Med，2024，30（6）：1016-1019.
  24. 24.
    FAN K N.Information extraction and knowledge graph construction of traditional Chinese medicine case records［D］.Huainan：Anhui University of Science and Technology，2024.
  25. 25.
    LI SY，WANG J N，LI Z N，et al.Rules on acupoint selection and treatment for epigastric pain based on the data mining of ancient acupuncture-moxibustion prescriptions［J］.Chin Acupunct Moxibust，2025，45（2）：253-261.
  26. 26.
    WANG X Y，GAO Y，LI B，et al.Prescription pattern of traditional Chinese medicine for treatment of hypertensive left ventricular hypertrophy based on multivariate data mining［J］.China J Chin Mater Med，2025，50（6）：1688-1698.
  27. 27.
    LU Y，GE C C，SHEN H ，et al.Analysis of core prescription and clinical efficacy of professor SHEN Hong's treatment of crohn's disease with dampness-stasis interjunction syndrome based on data mining［J］.J Nanjing Univ Tradit Chin Med，2024，40（7）：740-746.
  28. 28.
    ZHENG S D，ZHU R H，LI B，et al.Study on the mechanism of couplet medicines of Cortex Lycii and Cortex Moriin the treatment of diabetes mellitus based on network pharmacology and molecular docking［J］.Clin Res Pract，2021，6（33）：9-12，16.
  29. 29.
    LIU Y M，JI Y H，CHEN M J，et al.Gegen Qinlian decoction and its modified prescriptions ameliorate insulin resistance in type 2 diabetes mellitus：A review［J］.Chin J Exp Tradit Med Form，2024，30（15）：256-263.
  30. 30.
    HOU K K，CHEN L，ZHANG Z D，et al.Effect of astragalus on intestinal flora and GLP-1 in newly diagnosed type 2 diabetes mellitus patients with qi deficiency type［J］.Chin J Exp Tradit Med Form，2024，doi：.
  31. 31.
    REN J，BU Z L，LI X F，et al.Exploration of potential mechanism of Rehmanniae Radix Praeparata in treatment of type 2 diabetes mellitus based on bioinformatics and experiment［J］.Chin Tradit Herb Drug，2025，56（2）：566-584.
  32. 32.
    CHEN Q，LUO Y L，HU B，et al.Professor ZHANG Farong's experience in treating xiaoke disease with spleen-stomach strengthening and liver-kidney consolidating therapy［J］.Tradit Chin Med Res，2014，27（12）：32-34.
  33. 33.
    GUO X M，ZHANG Y P，ZHANG Y Z，et al.Analysis of Huopo Xialing decoction in treating obesity-type type 2 diabetes mellitus based on "dispersion，elimination，and purgation"［J］.China J Chin Med，2024，40（7）：740-746.
  34. 34.
    LI Q，LIU T.Effect of Erzhu Erchen decoction in the adjuvant treatment of obese type 2 diabetes mellitus （spleen deficiency and phlegm dampness syndrome） and its influences on oxidative stress indexes and insulin resistance［J］.Clin Res Pract，2024，9（33）：159-162.
  35. 35.
    WANG S Y，SHI Y C，WANG S D，et al.National master physician LV Renhe's empirical herb pairs for treating diabetes by regulating the middle jiao［J］.China J Chin Med，2022，37（1）：121-125.
  36. 36.
    FENG X Z.Clinical application and research review of traditional Chinese medicine in the prevention and treatment of diabetes［J］.Beijing J Tradit Chin Med，2022，41（3）：224-229.
  37. 37.
    WANG J J.The present situation and development trend of lipoprotein detection［J］.J Med Postgraduates，2016，29（1）：10-15.
  38. 38.
    MADDALONI E，BOLLI G B，FRIER B M，et al.C-peptide determination in the diagnosis of type of diabetes and its management：A clinical perspective［J］.Diabetes Obes Metab，2022，24（10）：1912-1926.
  39. 39.
    ZHANG C，MA X F，LIN W J，et al.Association between area under the C-peptide curve during an oral glucose tolerance test and diabetic retinopathy in type 2 diabetes patients［J］.J Diabetes Invest，2024，15（3）：315-325.
  40. 40.
    WANG Z Y，FAN X Y，JIA Y Z，et al.Characterization of animal models of type 2 diabetes mellitus with hypertension based on clinical symptoms in traditional Chinese and Western medicine［J］.Chin J Exp Tradit Med Form，2025，31（7）：230-236.

더 읽기

The above content is generated by Large Model Translation. The translated content is for reference only. We do not assume any commercial or legal responsibilty for any consequences arising from the use of our website